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Background: Bacillus Calmette-Guerin (BCG) is the standard treatment for patients with high-
risk non-muscle invasive bladder cancer (BC). Despite its success, about 30-50% of patients are 
refractory. It was reported that inducible nitric oxide synthase (iNOS) tumor expression is 
presented in 50% of human BC, associated with bad prognosis and BCG failure. 
Objective: to evaluate in human bladder tumors the association between iNOS expression and 
the tumor microenvironment focusing on the immunosuppressive protein S100A9. Also, 
investigate in a preclinical murine MB49-BC model the tumor immunoresponse induced by BCG 
in combination with the nitric oxide production inhibitor L-NAME. 
Results: In human bladder tumors, we detected a positive association between iNOS and 
S100A9 tumor expression, suggesting a relationship between both immunomodulatory proteins. 
We also found a positive correlation between iNOS tumor expression and the presence of 
S100A9+ tumor-infiltrating cells, suggesting an immunosuppressive tumor microenvironment 
induced by the nitric oxide production. 
Using the subcutaneous murine BC model, we show that similarly to the human pathology, MB49 
tumors constitutively expressed iNOS and S100A9 protein. MB49 tumor-bearing mice presented 
an immunosuppressive systemic profile characterized by fewer cytotoxic cells (CD8+ and NK) and 
higher suppressor cells (Treg and myeloid-derived suppressor cells -MDSC-) compared to normal 
mice. BCG treatment reduced tumor growth, increasing local CD8+-infiltrating cells and induced a 
systemic increase in CD8+ and a reduction in Treg. BCG combined with L-NAME, significantly 
reduced tumor growth compared to BCG alone, diminishing iNOS and S100A9 tumor expression 
and increasing CD8+-infiltrating cells in tumor microenvironment. This local response was 
accompanied by the systemic increase in CD8+ and NK cells, and the reduction in Treg and 
MDSC, even more than BCG alone. Similar results were obtained using the orthotopic BC model, 
where an increase in specific cytotoxicity against MB49 tumor cells was detected.  
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Conclusion: The present study provides preclinical information where NO inhibition in iNOS-
expressing bladder tumors could contribute to improve BCG antitumor immune response. The 
association between iNOS and S100A9 in human BC supports the hypothesis that iNOS 
expression is a negative prognostic factor and a promising therapeutic target.  
 
 






Bladder cancer (BC) is a common malignancy of the urological tract and ranks fourth in 
malignant cancer frequency in men in developed countries [1]. Immunotherapy with 
Bacillus Calmette-Guerin (BCG) has been used as gold standard therapy for in situ and 
non-muscle invasive (NMI) high histological grade BC treatment, to prevent recurrence 
and tumor progression [2]. However, it is still unknown why there are about 30-50% of 
patients that either fail to respond initially or relapse within the first years after treatment 
[3]. BCG successful depends on host immune system activation, which may exert an 
effective Th1-cytotoxic response, orchestrating the activity of CD8+, NK cells, 
macrophages and granulocyte cells [4]. A reduction in CD8+ and NK cytotoxic cells, with 
an increase in negative regulatory Treg and myeloid derived suppressor cells (MDSC) 
have been associated with low tumor immunogenicity [5, 6]. 
Tumor nitric oxide (NO) production by inducible nitric oxide synthases (iNOS) have been 
suggested as responsible for BCG therapy failure [7]. Furthermore, patients whose bladder 
tumors express iNOS, were related to bad prognosis, high invasion status and lower 
recurrence free time [8, 9]. Using a murine preclinical BC model developed in our 
laboratory, we proved that NO inhibition using the NOS inhibitor L-NAME is a good 
therapeutic strategy for tumors that constitutively express iNOS. L-NAME reduces tumor 
growth, invasion, development of metastases, angiogenic process, and enhances tumor 
growth inhibition induced by BCG [10, 11]. In cancer, high iNOS activity depletes L-
arginine, necessary for an effective immune response activation [12]. In tumor 
microenvironment, iNOS leads to the suppression of T cell expansion, inhibiting IL-2 
production by T cells and recruiting immunosuppressive cells such as MDSC [12, 13]. NO 
also reduces the affinity of T cell receptor to MHC-antigen complex, inhibiting cytotoxic 
activity [14]. NO inhibitors demonstrated to reduce breast tumor growth, associated with 
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the restore of the immune response, by reducing MDSC and expanding T cells [13, 15]. 
MDSC is a heterogeneous group that include immature granulocytes, macrophages, 
dendritic cells and myeloid progenitors. The increase in MDSC was associated with tumor 
progression in patients with BC [5, 16]. iNOS expression is a key event in acute 
inflammatory processes and this induction is physiologically reversed by transforming 
growth factor beta (TGF-β) [17-19]. However, TGF-β pathway is up-regulated in BC, 
associated with cancer-specific death [20]. In a chronic inflammatory environment as 
occurs in BC, both, iNOS and TGF-β are overexpress , generating an immunosuppressing 
tumor microenvironment, at least in part, by inducing S100A9 expression [21]. S100A9 is a 
member of S100 low molecular weight Ca2+-binding proteins. The majority of S100A9 
forms heterodimers with S100A8 (other member of S100 family) and could interact with 
three cell surface receptors in a wide range of different cells [22]. These receptors are 
Advanced glycation end product (RAGE), Toll-like receptor 4 (TLR4) and Extracellular 
matrix metalloproteinase inducer (CD147) [22]. In tumor cells, the interaction between 
S100A9 and these receptors activate the transcription factor NF-κB, inducing 
angiogenesis, tumor migration and proliferation [22, 23]. Alternatively, in immature myeloid 
cells, the binding of S100A9 to TLR4 induce MDSC differentiation [24]. S100A9 protein 
could be expressed by myeloid, as well as by tumor cells [24, 25]. Up-regulation of 
S100A9 in tumor cells also induces MDSC accumulation and Treg differentiation, which 
leads to the inability of host immune system to attack the tumor [24, 26, 27]. We previously 
reported that exist a positive correlation between iNOS and S100A9 tumor expression, 
suggesting an association among these two proteins [25]. Even more, we observed an 
increased number in S100A9+ tumor-infiltrating cells in invasive bladder tumors compared 
to NMI [25], suggesting that these immunosuppressive cells could be related to bad 
prognosis and the lack of BCG response. 
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Using the NMI MB49 murine preclinical BC model that express iNOS and produces NO, 
we observed that these tumors also express S100A9 and present high number of S100A9+ 
tumor-infiltrating cells as happens in tumors from patients with BC. Treatment with L-
NAME reduced S100A9 expression either in vitro and in vivo [25]. 
In the present study, we evaluated in human bladder tumor samples the association 
between iNOS tumor expression and S100A9 in tumor cells or in tumor-infiltrating cells. In 
addition, to understand if NO production could induce S100A9 and an immunosuppressive 
profile, we have evaluated the immune response induced in the preclinical MB49 high-
grade NMI BC model that naturally expresses iNOS. We also studied the BCG immune 
response in these iNOS-expressing tumors and the modulation by the NOS inhibitor, L-
NAME. Our results, either in BC patients or in our murine BC model, showed that iNOS 
tumor expression is associated with the expression of S100A9 in tumor cells and also 
correlates with the presence of S100A9+ tumor-infiltrating cells. The NOS inhibition with L-
NAME can induce a cytotoxic immune response and improved the BCG immunotherapy. 
 
 
2. MATERIALS AND METHODS 
 
Cells: Murine MB49 BC cells were cultured in RPMI1640 (GIBCO 31800-014), 2mM L-glutamine, 
80µg/ml gentamicin and 10% fetal bovine serum (FBS). 
BCG: Living Bacillus Calmette-Guerin (Pasteur1172 P2 strain-3x106CFU/mg/ml-) suspensions 
obtained from ANLISCG Malbrán-Argentina. 
L-NAME: Nω-nitro-L-arginine methyl ester; (sc-200333A Santa-Cruz-Biotechnology). 
In Vivo Tumor Growth: C57Bl/6J mice were obtained from animal facility at IOAHR. Institutional 
Review Board CICUAL approval: Res(CD)2012/02. Two animal models were used, subcutaneous 
(sc) in the flank (3x105 MB49 cells/100ul) and orthotopic in the bladder (3x104 MB49 cells/100ul) 
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as described [10, 11]. Normal group was inoculated with saline solution (ss). Tumor-bearing mice 
(TBM) were randomized in groups: Control, BCG, L-NAME and BCG+L-NAME. Normal, Control 
and L-NAME groups received ss while BCG and BCG+L-NAME received 2mg/ml of BCG twice a 
week intra-tumor for sc or intra-vesically for orthotopic tumors. L-NAME: 0.5 g/L in drinking water. 
Treatments started one day after tumor inoculation. Sc tumor growth was evaluated twice a week 
and tumor volume was calculated as  (R: longest and, r: shortest radio). Orthotopic tumor 
growth was evaluated as bladder weight and histological confirmation by Hematoxylin and Eosin 
(H&E). Mice were sacrificed 30 (sc) or 15 (orthotopic) days after tumor inoculation and tumor, 
spleen and draining lymph nodes were obtained. 
Histological Techniques: tumors were diagnosed by H&E technique. Immunostaining to iNOS 
(Abcam #15323); TGF-β (Santa Cruz Biotechnology #sc-146); S100A9 (Novus #NB110-89726) 
and CD8-Alexa488 (BD #557668) were performed. For Immunohistochemistry brown coloration 
represents positive protein expression. Colorimetric densitometry was calculated using ImageJ 
Package. Images from 7 tumors from each group were taken and one representative is shown. 
Flow Cytometry: Cells from spleen and inguinal draining lymph nodes were mechanically 
separated. Erythrocytes were lysed with NH4Cl 0.75%, Tris 0.2%, pH 7.2. 1x10
6 cells were 
labeled with: [CD45 (ab25046); CD8 (ab95588); CD4 ab86858); CD25 (ab25534), FOXP3 
(ab210231); GR1 (ab24884); CD11b (ab86879) from AbCam, and NK1.1 (BD#557391); CD45 
(109807-BioLegend)]. Beccton Dickinson Facscalibur flow cytometer was used. Data were 
analyzed with Cyflogic Package. 
Cytotoxic assay against MB49 cells: After 4 days of stimulation with MB49 cells previously 
inactivated with Mitomycin C (100ug/ml), splenocytes were harvested and seeded onto 
monolayer of living MB49 cells (ratio 10:1 splenocytes:tumor cells). Cytotoxic activity was 
evaluated by MTS (Promega) as absorbance 492/620nm (Ab). %Cytotoxicity was calculated as: 
1-[Ab(MB49+splenocytes)-(splenocytes)] x100/ Ab(MB49). 
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Human tumor samples: Paraffin sections of 21 bladder tumors were obtained from the 
Pathology Department of IOAHR, and immunohistochemistry for iNOS and S100A9 were made 
(Protocol approved by the institutional committee of ethics). Samples: 12 male, 9 female. Median 
age: 63.1 years (standard deviation: 11.7). Invasion status: 3 pTa; 14 pT1; 4 pT2. 
ImageJ Package was used to calculate the proportion of positive iNOS and S100A9 cells. A linear 
mixed model was used to calculate the association between iNOS and S100A9 in human bladder 
tumors. Pearson Test was used to evaluate the correlation between iNOS tumor expression and 
S100A9+ tumor-infiltrating cells. 
Statistical Analysis: All experiments were performed three times with at least 3 mice per group. 
Results were expressed as the mean and SD. ANOVA with Tukey’s Multiple Comparison with 
3.01 Graph-Pad-InStat statistical or R Version 1.1.453 software was used. p≤0.05 was 




3.1. iNOS is associated with the expression of the immunosuppressive protein S100A9 in 
human bladder tumors 
To analyze the association between iNOS and S100A9 in human BC, their expression were 
evaluated by immunohistochemistry. Figure 1A shows representative images of S100A9 
expression in human bladder tumors. We found three different patterns of S100A9 expression. 
The protein could be expressed in tumor cells, tumor-infiltrating cells, in cells circulating in blood 
vessels, or in the combination of those three patterns. In Figure 1B two representative images of 
positive and negative samples for iNOS and S100A9 are shown. Bladder tumor from Patient 1 is 
negative for iNOS and S100A9, while tumor from Patient 2 is positive for iNOS and S100A9 in 
tumor cells and in tumor-infiltrating cells. The evaluation with a linear mixed model indicates that 
the proportion of tumor cells expressing iNOS significantly predicts those tumor cells expressing 
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S100A9 (p=0.00137). The increase in S100A9 tumor cells was evident when iNOS values were 
high. For this reason, the relationship between both proteins was evaluated as dichotomous 
variable. When iNOS expression was equal to, or greater than 90% (that is, the entire tumor is 
positive for iNOS), it presents a more significant association with a higher S100A9 tumor 
expression (p=0.000863). We also found a positive correlation between iNOS tumor expression 
and S100A9+ tumor-infiltrating cells using a Pearson correlation test (Figure 1C). These results 
support that iNOS tumor expression is associated with S100A9 and suggest that iNOS could 
induce an immunosuppressive tumor microenvironment. 
 
3.2. Tumor growth inhibition by BCG+L-NAME was accompanied by the reduction of iNOS, 
TGF-β, and S100A9 expression and the increase of CD8+-infiltrating cells 
To analyze the effect of BCG, L-NAME or its combination (BCG+L-NAME) on tumor growth 
inhibition we performed a sc ectopic approach. Sc MB49 TBM treated with BCG, L-NAME or 
BCG+L-NAME presented a reduction in tumor volume of 78%, 50% and 95.5% respectively, 
compared to Control (Figures 2A-B). In Figures 2C-F we analyzed the expression of iNOS, 
TGF-β, S100A9 and CD8 in sc MB49 tumors. iNOS, TGF-β and S100A9 were intensely 
expressed in Control MB49 tumors, and few CD8+-infiltrating cells were found. BCG did not 
significantly modify iNOS or S100A9 expression but was able to reduce TGF-β expression and to 
induce a 5-fold increase in CD8+-infiltrating cells. L-NAME reduced TGF-β and S100A9 
expression and also induced a 5-fold increase in CD8+-infiltrating cells. The combined treatment 
of BCG+L-NAME reduced the expression of iNOS, TGF-β and S100A9 and recruited a 10-fold 
increase in CD8+-infiltrating cells compared to Control group. These results suggest that the use 
of a NO production inhibitor could modulate the immunosuppressive microenvironment affecting 
the expression of TGF-β and S100A9 and inducing a recruitment of CD8+ cells. 
 
3.3. L-NAME enhances BCG-induced immune response 
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Immune cell populations were evaluated in spleen and draining lymph nodes (DLN) from Normal 
and sc MB49 TBM. While MB49 Control group presented a reduction in CD8+ compared to 
Normal mice in both organs, BCG or L-NAME restored them to normal values in spleen, but not in 
the DLN. Only the combination of BCG+L-NAME normalized the number of CD8+ in DLN and 
increased them even more than the Normal group in spleen (Figures 3A and 4A). NK cells were 
also reduced in Control group compared to Normal mice. In spleen, only BCG+L-NAME treatment 
incremented NK cells compared to Control (Figure 3B); while in DLN it was L-NAME (alone or 
combined with BCG) the responsible for increased NK cells (Figure 4B).  
Regarding to immunosuppressive populations, Treg cells were higher in spleen and DLN from 
Control TBM than in Normal mice. In the spleen, all treatments reduced Tregs; while in DLN it 
was BCG (with or without L-NAME) who restored Tregs to normal values (Figures 3C and 4C). 
MDSC were also higher in Control TBM. In spleen was BCG+L-NAME and in DLN was L-NAME 
(with or without BCG) the responsible for reduced MDSC compared to Control group (Figures 3D 
and 4D). 
These results show that sc MB49 tumors generate an immune profile characterized by a 
decrease in CD8+ and NK cells and an increase in Treg and MDSC. BCG partially inhibits some 
of these systemic immunosuppressive parameters in TBM, but not all. Only the combination of 
BCG with L-NAME was enough to revert the immunosuppressive profile observed in MB49 TBM 
and to restore the immune cell populations to values compared to an animal without tumor. 
 
3.4. L-NAME enhanced orthotopic bladder tumor growth inhibition and the antitumor 
immune response induced by BCG 
Since the BCG inoculation site could affect the immune response developed, we decided to 




L-NAME treatment reduced orthotopic tumor growth, being BCG+L-NAME more effective in this 
inhibition (Figure 5A). Tumor incidence was confirmed by histologic analysis. Figure 5B shows 
that L-NAME (alone or combined with BCG) reduced the proportion of mice with tumor at the time 
of sacrifice. BCG showed a lower trend in tumor incidence that was not significant in this study 
from these iNOS-expressing tumors (Figure 5B). 
The cytotoxic capability against MB49 cells from splenocytes of TBM from each experimental 
group was performed (Figure 5C). Splenocytes from Control TBM had lower specific MB49 
cytotoxicity than Normal mice. BCG, L-NAME or BCG+L-NAME treatment revert this effect, 
increasing the cytotoxicity compared to Control group and restored to normal values. Immune cell 
populations were analyzed in spleen from the orthotopic model. Control TBM had fewer CD8+ 
cells than Normal group and only BCG+L-NAME was enough to increase CD8+ cells compared to 
Control (Figure 5D). NK cells were also reduced in Control TBM compared to Normal mice, but 
regarding to these cells, all treatments increased them compared to Control group. However, only 
the combined treatment of BCG+L-NAME significantly increased NK cells even more than Normal 
mice (Figure 5E). As previously observed in the sc model, Tregs were higher in spleen from 
Control TBM compared to Normal and they were reduced by all treatments (Figure 5F). Control 
TBM presented an increment in MDSC compared to Normal group and only BCG+L-NAME 
reduced them compared to Control (Figure 5G). These data demonstrate that orthotopic MB49 
tumors generate an immunosuppressive profile like those observed in the sc model, 
characterized by a reduction of CD8+ and NK cells, and an increase in Treg and MDSC. The 
major difference between BCG alone or combined with L-NAME is not only the significant tumor 
growth inhibition, but also the increase in CD8+ and the reduction in MDSC. Thus, L-NAME was 
able to improve the tumor reduction and incidence and the immune response induced by BCG in 







The success of BCG immunotherapy for BC requires a competent host immune system [2, 3], 
where CD8+ and NK cells are fundamental participants, since their depletion has been associated 
with loss of BCG-antitumor activity [4]. Also, it was shown that BCG is not effective in athymic 
mice [4]. On the other hand, Treg and MDSC inhibit immune cytotoxic cells slowing the removal 
of tumor cells and promoting tumor growth [16, 26, 28]. Recent studies showed that bladder 
tumors secreted chemokines that recruit regulatory cells and BCG was not able to modify this 
effect [29]. Among others, the expression of immunosuppressive molecules such as iNOS and 
S100A9 were described [12, 28, 30]. These molecules could contribute to BCG therapeutic 
failure, generating an immunosuppressive tumor microenvironment. It was demonstrated that 
about 50% of patients with BC present iNOS tumor expression, associated with worse prognosis 
[8], and linked to BCG failure [7]. In the present study, we first evaluated the association between 
iNOS and S100A9 expression in human bladder tumors. We found that iNOS positive tumors are 
related with the expression of S100A9, not only at tumor cells, but also in tumor-infiltrating cells. 
These results raises the hypothesis that iNOS expression could be generating an 
immunosuppressive tumor microenvironment. If this idea is correct, inhibitors of NO production 
combined with BCG may reverse the immunosuppression and contribute to control tumor growth. 
To test this hypothesis, we used a preclinical MB49 BC model that constitutively expresses iNOS, 
closely related to human pathology [9, 10]. Our results showed that in the heterotopic model, 
BCG, L-NAME and its combination reduced MB49 tumor growth. However, only L-NAME alone or 
combined with BCG reduced orthotopic tumor growth and incidence. In the subcutaneous model, 
it was observed that the inhibition of NO production by L-NAME was enough to reduce S100A9 
expression. This protein can be produced either by immune cells or by tumor cells [21, 24, 25] 
and have been associated with an immunosuppressive microenvironment, inducing suppressor 
cells differentiation (Treg and MDSC) and inhibiting cytotoxic cells [21, 28, 30, 31]. S100A9 
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binding to its receptors on different cells from tumor microenvironment leading a variety of 
different responses [22]. It has been shown that in tumor cells S100A9 induces its proliferation, 
since its inhibition leads to a reduction in tumor growth [23]. On the other hand, in immune cells, 
S100A9 is a potent inducer of MDSC differentiation and expansion [24]. Thus, S100A9 is a 
prominent participant in tumor growth and in the immunosuppression developed. Similar to that 
observed in human bladder tumors, in our murine BC model we found that iNOS and S100A9 
were associated, while the inhibition of NO production not only reduce S100A9, but also recruit 
CD8+-infiltrating tumor cells. One candidate protein that could link the relation between iNOS and 
S100A9 is the immunosuppressive factor TGF-β. TGF-β is usually expressed to protect and 
prevent the normal tissue damage in response to chronic inflammation process induced by iNOS 
activity [19]. Tumors also use this protein as a growth factor to proliferate and to evade the 
immune response, inhibiting cytotoxic cells and inducing Tregs and MDSC [30, 31]. Furthermore, 
it was described that TGF-β expressed in tumor microenvironment is capable induce S100A9 
expression [26], associated with the recruiting of suppressor cells [21, 27]. Reinforcing this idea, 
we observed that in our murine BC model, MB49 tumors present high TGF-β expression and 
BCG and L-NAME (alone or combined with BCG) reduced this factor. This inhibition in TGF-β 
pathway by all treatments may contribute to revert the tumor immunosuppressive 
microenvironment. Other authors demonstrated that tumor TGF-β production induces a systemic 
immune suppression and inhibits host immunesurveillance. Similar to us, they also observed that 
its neutralization increases the infiltration of inflammatory immune cells and enhances the 
antitumor immune response mediated by CD8+ and NK cytotoxic cells [32]. 
In our study, the evaluation of immune populations showed that CD8+ and NK cytotoxic effectors 
were decreased in periphery (spleen and DLN) of sc and orthotopic MB49 TBM. An increase in 
suppressor cells Treg and MDSC was also observed. These results indicate that MB49 iNOS-
expressing tumors generate a systemic immunosuppressive profile, similar to that observed in 
other iNOS-expressing tumors [12-14]. BCG treatment combined with L-NAME changed the 
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immune profile, increasing cytotoxic effectors cells and decreasing suppressor immune cells. It 
was previously shown that MB49 tumors express iNOS, produce NO [10] and that BCG induces 
both iNOS and NO production [33]. These results, added to current ones, indicate that iNOS 
expression generates either, systemic and tumor immunosuppressive microenvironment. 
Moreover, a recent study showed that NO inhibition in iNOS-expressing tumors down-regulates 
suppressive immune response and enhances other immunotherapies based on checkpoint 
blockade [34]. As shown in the orthotopic model, NO inhibition with L-NAME reduced bladder 
tumor growth and incidence and induced specific spleen cytotoxicity against MB49 tumor cells. 
BCG treatment increased specific cytotoxicity, but this response was not enough to significantly 
reduce bladder tumor growth. However, BCG+L-NAME induced a similar spleen specific MB49 
cytotoxicity that was observed for BCG or L-NAME alone, while it did reduce bladder tumor 
growth. Globally, the combined treatment of BCG+L-NAME presented a higher orthotopic tumor 
growth inhibition and a powerful systemic change of the immune profile. Our findings are in 
agreement with data from other author, who showed that BCG therapy induced the immune 
cytotoxic activation but it was not able to completely down-regulate the suppressive response 
induced in human bladder tumors [4, 29]. Furthermore, here we demosntrated that similar to other 
iNOS-expressing tumors, the use of a NO production inhibitor such as L-NAME reduce tumor 
growth and restore a competent immune response [15]. 
In summary, our results show that iNOS expression in BC patients could induce an 
inmunosuppressive tumor microenvironment at least related with the expression of S100A9 in 
tumor cells and the recruitment of S100A9+ tumor-infiltrating cells. The preclinical model shows 
that NO production by iNOS enzyme induces S100A9 expression. The iNOS activity inhibition by 
L-NAME reduced S100A9 and increased the recruitment of cytotoxic CD8+-infiltrating cells. The 
combination of BCG with NO inhibitors could contribute to reverse the immunosuppression and 
the lack of response to BCG in iNOS-expressing tumors. This preclinical study highlights the need 
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This study provides useful preclinical information demonstrating that NO inhibition could improve 
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10.1. Figure 1: Association between iNOS and S100A9 in human bladder tumors: A) 
Immunohistochemistry for S100A9 in human bladder tumors. Three representative 
patterns of S100A9 expression are shown in brown coloration. Green arrows: positive 
S100A9 tumor expression. Blue arrows: positive S100A9+ tumor-infiltrating cells. Red 
arrows: positive S100A9 cells in blood vessels. B) Immunohistochemistry for iNOS (left 
panels) and S100A9 (right panels) in two representative samples of human bladder 
tumors. Brown coloration indicates positive expression. Bladder tumor from Patient 1 
(upper panels) is negative for iNOS and S100A9 expression. Bladder tumor from Patient 2 
(bottom panels) is positive for iNOS and S100A9 proteins. Black arrows: negative iNOS 
tumor expression. Yellow arrows: negative S100A9 tumor expression. White arrow: 
positive iNOS tumor expression. Green arrows: positive S100A9 tumor expression. Blue 
arrows: positive S100A9+ tumor-infiltrating cells. C) Pearson correlation test between 
iNOS tumor expression and S100A9+ tumor-infiltrating cells. p=0.0001; r=0.06; R2=0.31. 
 
10.2. Figure 2: Evaluation of heterotopic tumor growth in response to BCG and L-
NAME treatment: Heterotopic tumor volume was evaluated with BCG treatment and/or 
with the NO production inhibitor L-NAME. A) MB49 sc tumor growth curves and B) MB49 
tumoral volume (mm3) after 30 days post-inoculation. BCG (b:p<0.001), L-NAME 
(a:p<0.05) or BCG+L-NAME (c:p<0.0001) reduced tumor growth compared to Control 
group. BCG+L-NAME presented a higher inhibition compared to BCG (d:p<0.05) or L-
NAME (e:p<0.01) alone. ANOVA – Tukey´s Multiple Comparison. C) 
Immunohistochemistry for iNOS. A representative image from each experimental group is 
shown. Brown coloration indicates positivity protein expression. Densitometry 
quantification of iNOS expression in 7 tumors of each group. Control: 1.00±0.06, BCG: 
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1.15±0.07; L-NAME: 0.85±0.09; BCG+L-NAME: 0.72±0.13 ab. a:p<0.05 vs. Control and 
b:p<0.01 vs. BCG. ANOVA – Tukey´s Multiple Comparison. D) Immunohistochemistry for 
TGF-β. A representative image from each experimental group is shown. Brown coloration 
indicates positivity protein expression. Densitometry quantification of TGF-β expression in 
7 tumors. Control: 1.00±0.44, BCG: 0.29±0.20a; L-NAME: 0.02±0.02b; BCG+L-NAME: 
0.11±0.16b. a:p<0.05 and b:p<0.01 vs. Control. ANOVA – Tukey´s Multiple Comparison. 
E) Immunohistochemistry for S100A9. A representative image from each experimental 
group is shown. Brown coloration indicates positivity protein expression. Densitometry 
quantification of S100A9 expression in 7 tumors. Control: 1.00±0.07, BCG: 0.66±0.25; L-
NAME: 0.16±0.06a; BCG+L-NAME: 0.34±0.24b. a:p<0.01 and b:p<0.05 vs. Control. 
ANOVA – Tukey´s Multiple Comparison. F) Immunofluorescence for CD8+. A 
representative image from each experimental group is shown. Green coloration indicates 
positivity cell presence. Nuclei were stained with DAPI in blue coloration. Percentage of 
CD8+ cells respect to total nuclei was quantify. Control: 4.29±5.73, BCG: 25.34±6.20a; L-
NAME: 24.45±13.55a; BCG+L-NAME: 40.70±14.84b. a:p<0.05 and b:p<0.001 vs. Control. 
ANOVA – Tukey´s Multiple Comparison. C-D-E-F) Median and standard deviation (n=7) 
were included in the left corner of the images. 
 
10.3. Figure 3: Evaluation of immune cell populations in spleen of sc MB49 TBM: 
Spleen from Normal mice or sc MB49 TBM treated with or without BCG and L-NAME. 
Evaluation of immune populations by flow cytometry, leukocytes were first selected using 
CD45.2+ antigen. One representative assay of three is shown. Statistical analysis with 
ANOVA – Tukey´s Multiple Comparison. A) CD8+ cells are low in spleen from Control TBM 
compared to Normal mice (a:p<0.05), while BCG (c:p<0.01), L-NAME (d:p<0.05) or 
BCG+L-NAME (e:p<0.0001) increased them compared to Control. BCG+L-NAME 
increased CD8+ even more than Normal (b:p<0.001) or L-NAME (f:p<0.01) groups. B) NK 
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cells (NK1.1+) are low in spleen from Control TBM compared to Normal mice (a:p<0.05), 
while BCG+L-NAME increased them compared to Control (b:p<0.01). C) Treg cells 
(CD4+CD25+FOXP3+) in total CD4+ cells are high in spleen from Control TBM compared to 
Normal mice (a:p<0.05), while BCG (b:p<0.0001), L-NAME (c:p<0.05 ) or BCG+L-NAME 
(b:p<0.0001) reduce their number compared to Control. BCG and BCG+L-NAME reduce 
Treg even less than Normal mice (a:p<0.05). D) MDSC (Gr1+CD11b+) are high in spleen 
from Control TBM (a:p<0.001) or BCG TBM (b:p<0.05 ) compared to Normal mice. Only 
the combined treatment of BCG+L-NAME significantly reduces their number compared to 
Control (c:p<0.01).  
 
10.4. Figure 4: Evaluation of immune cell populations in DLN of sc MB49 TBM: 
Inguinal draining lymph node (DLN) from Normal or sc MB49 TBM treated with or without 
BCG and L-NAME. Evaluation of immune populations by flow cytometry, leukocytes were 
first selected using CD45.2+ antigen. One representative assay of three is shown. 
Statistical analysis with ANOVA – Tukey´s Multiple Comparison. A) CD8+ cells are low in 
DLN from Control TBM compared to Normal mice (a:p<0.05). BCG partially increase CD8+ 
compared to Control (d:p<0.01), but BCG (b:p<0.05) and L-NAME (c:p<0.001) alone 
continue to present fewer CD8+ than Normal group. BCG+L-NAME increase CD8+ 
compared to Control (e:p<0.001). B) NK cells (NK1.1+) are also low in DLN from Control 
TBM compared to Normal mice (a:p<0.05). L-NAME (b:p<0.01) or BCG+L-NAME 
(c:p<0.05) enhance their number compared to Control. C) Treg cells (CD4+CD25+FOXP3+) 
in total CD4+ cells are high in DLN from Control TBM and L-NAME TBM compared to 
Control (a:p<0.05). BCG or BCG+L-NAME reduce Treg compared to Control (b:p<0.0001) 
or even to Normal mice (a:p<0.05). BCG+L-NAME present lower Treg compared to L-
NAME alone (c:p<0.0001). D) MDSC (Gr1+CD11b+) are also high in DLN from Control 
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TBM compared to Normal mice (a:p<0.05). L-NAME or BCG+L-NAME reduce their 
number compared to Control (b:p<0.05).  
 
10.5. Figure 5: Evaluation of orthotopic tumor growth and splenic cytotoxic 
antitumor response by BCG, L-NAME and BCG+L-NAME treatment: Normal bladder 
or orthotopic MB49 bladder TBM treated with or without BCG (endovesical) and L-NAME 
(drinking water). A pool of two assays are shown. A) Tumor size determined as bladder 
weight at the time of sacrifice. Bladders from Control TBM (a:p<0.001) or BCG TBM 
(b:p<0.01) present a higher weight compared to Normal bladder. L-NAME (c:p<0.001) and 
BCG+L-NAME (d:p<0.0001) reduce bladder weight compared to Control. BCG+L-NAME 
present lower bladder weight compared to BCG alone (e:p<0.01). ANOVA – Tukey´s 
Multiple Comparison. B) Bladder tumor incidence is represented as the percentage of 
mice with tumor confirmed by histology with H&E. Control: 87%; BCG: 74%; L-NAME: 
58%; BCG+L-NAME: 57%. Tumor incidence is lower in L-NAME and BCG+L-NAME group 
compared to Control TBM. *:p<0.05; Chi2 Test. C) Specific splenocyte cytotoxic response 
against MB49 cells. Splenocytes from Control TBM are less cytotoxic against tumor cells 
than Normal splenocytes (a:p<0.05). BCG (b:p<0.05), L-NAME (c:p<0.001) or BCG+L-
NAME (c:p<0.001) increase the cytotoxicity compared to Control. D to G) Evaluation of 
immune populations in spleen by flow cytometry: leukocytes were first selected using 
CD45.2+ antigen. A pool of two assays are shown. ANOVA – Tukey´s Multiple 
Comparison. D) CD8+ cells are low in spleen from Control TBM compared to Normal mice 
(a:p<0.001). Only BCG+L-NAME increases CD8+ compared to Control (b:p<0.05). E) NK 
cells (NK1.1+) are low in Control TBM compared to Normal mice (a:p<0.05), while BCG 
(b:p<0.05), L-NAME (b:p<0.05) or BCG+L-NAME (d:p<0.0001) increase their values 
compared to Control. Only BCG+L-NAME increases NK cells even more than Normal mice 
(c:p<0.05). F) Treg cells (CD4+CD25+FOXP3+) in total CD4+ cells are high in Control TBM 
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compared to Normal mice(a:p<0.05). BCG (b:p<0.01), L-NAME (c:p<0.05) or BCG+L-
NAME (b:p<0.01) reduce Treg compared to Control. G) MDSC (Gr1+CD11b+) are high in 
Control TBM (a:p<0.001) and in BCG TBM (b:p<0.05) compared to Normal mice. Only 









• iNOS expression is associated with bad prognosis in patients with bladder cancer. 
 
• We found an association between iNOS and the immunosuppressive protein 
S100A9. 
 
• iNOS inhibition using L-NAME increases CD8+ and NK cells and reduces Treg and 
MDSC. 
 
• iNOS inhibition using L-NAME reduces the expression of S100A9 and TGF-β. 
 
• L-NAME improves BCG tumor growth inhibition and the antitumor immune 
response. 
